Cargando…

Krüppel‐like factor 4 promotes c‐Met amplification‐mediated gefitinib resistance in non‐small‐cell lung cancer

Gefitinib has been widely used in the first‐line treatment of advanced EGFR‐mutated non‐small‐cell lung cancer (NSCLC). However, many NSCLC patients will acquire resistance to gefitinib after 9‐14 months of treatment. This study revealed that Krüppel‐like factor 4 (KLF4) contributes to the formation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Wei, Xie, Qianyi, Liu, Suo, Ji, Ying, Li, Chunyun, Wang, Chunle, Jin, Longyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989843/ https://www.ncbi.nlm.nih.gov/pubmed/29624806 http://dx.doi.org/10.1111/cas.13601

Ejemplares similares

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer: HMGB1-mediated autophagy promotes gefitinib resistance
por: Lei, Tianyao, et al.
Publicado: (2022)

Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification
por: Jang, Won-Jun, et al.
Publicado: (2014)

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
por: Ruan, Ji
Publicado: (2021)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
por: Ju, Lixia, et al.
Publicado: (2013)

Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance
por: Han, Shuangze, et al.
Publicado: (2022)

ROS1 amplification mediates resistance to gefitinib in glioblastoma cells
por: Aljohani, Hashim, et al.
Publicado: (2015)

Marsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells
por: Han, Shu-Yan, et al.
Publicado: (2017)

Deletion of Krüppel-like factor-4 promotes axonal regeneration in mammals
por: Xu, Jin-Hui, et al.
Publicado: (2020)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
por: Wang, Xiaomeng, et al.
Publicado: (2021)

Deoxypodophyllotoxin Inhibits Cell Growth and Induces Apoptosis by Blocking EGFR and MET in Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Kim, Han Sol, et al.
Publicado: (2021)

Krüppel-like Factor 13 Promotes HCC Progression by Transcriptional Regulation of HMGCS1-mediated Cholesterol Synthesis
por: Chen, Chao-Chun, et al.
Publicado: (2022)

Kruppel like factor 16 promotes lung adenocarcinoma progression by upregulating lamin B2
por: Jiao, Xiaodan, et al.
Publicado: (2022)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib
por: Jin, Qian, et al.
Publicado: (2021)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Picropodophyllotoxin Inhibits Cell Growth and Induces Apoptosis in Gefitinib-Resistant Non-Small Lung Cancer Cells by Dual-Targeting EGFR and MET
por: Lee, Jin-Young, et al.
Publicado: (2023)

Participation of Krüppel-like Factors in Atherogenesis
por: Kotlyarov, Stanislav, et al.
Publicado: (2023)

Krüppel-like factors compete for promoters and enhancers to fine-tune transcription
por: Ilsley, Melissa D., et al.
Publicado: (2017)

Kruppel‐like factor 6 promotes macrophage inflammatory and hypoxia response
por: Kim, Gun‐Dong, et al.
Publicado: (2020)

Helicobacter Pylori Promotes the Expression of Krüppel-Like Factor 5, a Mediator of Carcinogenesis, In Vitro and In Vivo
por: Noto, Jennifer M., et al.
Publicado: (2013)

CXCR4 promotes gefitinib resistance of Huh7 cells by activating the c‐Met signaling pathway
por: Zhao, Dali, et al.
Publicado: (2021)

Eugenol protects the transplanted heart against ischemia/reperfusion injury in rats by inhibiting the inflammatory response and apoptosis
por: Feng, Wei, et al.
Publicado: (2018)

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
por: Liam, Chong Kin, et al.
Publicado: (2023)

Role of promoting inflammation of Krüppel-like factor 6 in acute kidney injury
por: Li, Dan, et al.
Publicado: (2020)

Krüppel-like factor 4: A new potential biomarker of lung cancer
por: FADOUS-KHALIFÉ, MARIE CLAUDE, et al.
Publicado: (2016)

Expression of Kruppel-like factor 8 and Ki67 in lung adenocarcinoma and prognosis
por: Liu, Yifei, et al.
Publicado: (2017)

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
por: Ding, Caixia, et al.
Publicado: (2023)

Krüppel-like transcription factors and control of pluripotency
por: Bourillot, Pierre-Yves, et al.
Publicado: (2010)

Krüppel-like factors: Three fingers in control
por: Swamynathan, Shivalingappa K
Publicado: (2010)

Sp1- and Krüppel-like transcription factors
por: Kaczynski, Joanna, et al.
Publicado: (2003)

Kruppel-like Factors in Skeletal Physiology and Pathologies
por: Abe, Makoto, et al.
Publicado: (2022)

The Involvement of Krüppel-like Factors in Cardiovascular Diseases
por: Santoyo-Suarez, Michelle G., et al.
Publicado: (2023)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
por: Watermann, I., et al.
Publicado: (2015)

The Krüppel-like factor 2 and Krüppel-like factor 4 genes interact to maintain endothelial integrity in mouse embryonic vasculogenesis
por: Chiplunkar, Aditi R, et al.
Publicado: (2013)

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
por: Lu, Xiangdong, et al.
Publicado: (2021)

PKC signal amplification suppresses non-small cell lung cancer growth by promoting p21 expression and phosphorylation
por: Liu, Shuyan, et al.
Publicado: (2022)

miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met
por: Cao, Xiaonian, et al.
Publicado: (2017)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sucjjpqj3frgp1vi5cnv27pc9m